Teva does comparatively well under ObamaCare because Copaxone has little exposure to Medicaid. Moreover, the new regulatory pathway for biogenerics/biosimilars should help Teva in due course.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.